Home / Themes / Data Owners '25: Healthcare, Claims & Clinical Data
Data Owners '25: Healthcare, Claims & Clinical Data (view performance)
Last updated
Theme no thesis · 2/5 sections · Tickers 10 with notes · 10 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Overview
Hiring Trend Watchpoints
High-performing operators in this theme are expected to show robust hiring in specialized technical and commercial roles. We anticipate strong demand for **AI/ML Engineers and Data Scientists** to develop and deploy AI agents, build foundation models, and manage vast multimodal datasets, as seen with IQVIA's 294 deployed AI agents and Tempus AI's 500+ petabyte data library. **Clinical Trial and R&D Specialists** (e.g., CRAs, biostatisticians, clinical data managers) will be in demand due to accelerated R&D Solutions growth and robust Emerging Biopharma funding, benefiting companies like IQVIA and Labcorp. **Reimbursement and Regulatory Specialists** will be critical to navigate complex landscapes, secure ADLT status, and gain MolDx and commercial payer coverage for new diagnostics, impacting Guardant Health, Tempus AI, and Quest Diagnostics. Lastly, **Specialty Diagnostics Sales and Market Access teams** will expand to drive adoption of high-growth products like Guardant Health's Shield and Quest Diagnostics' AD-Detect.
**Confirmation of strengthening:** Increased job postings for AI/ML roles, clinical trial roles, and specialty diagnostic sales. Mentions of expanding data science teams, successful regulatory approvals leading to new commercial hires, and investments in digital health platforms.
**Warning of deterioration:** Hiring freezes in R&D or data science. Significant layoffs in commercial teams for new products. Increased focus on cost-cutting through automation without corresponding investment in innovation roles. Delays in regulatory/reimbursement roles.
Forum Watchlist
- Reddit — r/healthtechHigh
Discussions on new technologies, AI applications, and startups in healthcare.
- Reddit — r/bioinformaticsMedium
Trends in genomic data analysis, precision medicine, and molecular diagnostics.
- Reddit — r/clinicalresearchMedium
Updates on clinical trial methodologies, data management, and CRO industry trends.
- Professional Forum — HIMSS CommunityHigh
Discussions on healthcare IT, EHR interoperability, and data analytics adoption by health systems.
- Professional Forum — ASCO Connection (Oncology Professionals)High
Clinical utility and adoption of liquid biopsies, MRD testing, and precision oncology data.
- Investor Forum — Seeking Alpha (IQV, TEM, GH, DGX)Medium
Investor sentiment, analyst debates, and reactions to earnings/guidance for theme constituents.
Industry Publications
- Fierce Biotech (fiercebiotech.com) — Covers biotech funding, drug development, clinical trials, and emerging biopharma, directly relevant to IQV, TEM, CERT.
- Fierce Pharma (fiercepharma.com) — Focuses on pharmaceutical industry news, R&D, commercialization, and data utilization by large pharma, impacting IQV, VEEV, TEM.
- Fierce Healthcare (fiercehealthcare.com) — Reports on health systems, payers, policy, and digital health, crucial for UNH, CVS, ELV, CI, ORCL, HCAT.
- GenomeWeb (genomeweb.com) — Specializes in genomics, proteomics, and molecular diagnostics, essential for GH, TEM, NTRA, ABT, DGX, LH.
- STAT News (statnews.com) — In-depth coverage of biotech, pharma, health policy, and scientific breakthroughs, offering broad theme relevance.
- Modern Healthcare (modernhealthcare.com) — Covers business and policy aspects of healthcare, including data management, AI adoption, and payer strategies.
- Endpoints News (endpts.com) — Focuses on biopharma news, clinical trials, and M&A, providing insights into R&D and data-driven drug development.
- Health Affairs (healthaffairs.org) — Peer-reviewed journal on health policy, research, and healthcare delivery, offering insights into regulatory and systemic changes.
Second Order Trends
Several second-order trends are emerging within the 'Healthcare, Claims & Clinical Data' theme:
1. **AI-Native Drug Discovery & Development:** Beyond traditional data analytics, companies like IQVIA and Tempus AI are actively leveraging AI to accelerate drug discovery and development. IQVIA's deployment of 294 AI agents and Tempus AI's focus on building foundation models with pharma partners (e.g., AstraZeneca, Merck, Gilead) indicate a shift towards AI as a core engine for R&D, not just a supporting tool. This suggests a new frontier for data monetization through AI-powered insights and predictive modeling in the biopharma sector.
2. **Maturing Precision Oncology & Multi-Cancer Early Detection:** The theme is seeing significant advancements and commercial traction in precision oncology, particularly with liquid biopsies and minimal residual disease (MRD) testing. Guardant Health's FDA approval for Guardant360 Liquid CDx and the inclusion of its Shield test in ACS guidelines, alongside Quest Diagnostics' Haystack MRD and Tempus AI's MRD efforts, highlight a maturing market for these advanced diagnostics. The focus is now shifting from technological feasibility to widespread clinical adoption and favorable reimbursement, making regulatory wins and payer coverage critical inflection points.
3. **Integrated Payer-Provider-PBM Data for Value-Based Care:** Large integrated healthcare players like UnitedHealth Group, CVS Health, and Elevance Health are increasingly combining their vast claims, pharmacy benefit management (PBM), and care delivery data assets. Elevance Health's Carelon segment and its AI investments for medical cost management exemplify the strategic imperative to leverage this integrated data for more precise clinical interventions, improved member engagement, and ultimately, better outcomes within value-based care models. This trend emphasizes the power of holistic data ownership across the healthcare continuum.
4. **Regulatory & Reimbursement as a Strategic Moat:** The consistent emphasis on navigating complex regulatory pathways (e.g., ADLT status, MolDx) and securing favorable reimbursement (e.g., PAMA, Medicare Advantage coverage, commercial payer negotiations) across multiple theme constituents (DGX, GH, LH, TEM) underscores that regulatory and reimbursement expertise is becoming a key competitive differentiator. Success in these areas directly impacts market access, average selling prices (ASPs), and profitability, effectively acting as a strategic moat for companies with robust regulatory and market access capabilities.
Search Keywords Brand Product
- Guardant360 Liquid CDx
- Shield blood test
- Reveal Ultra
- InfinityAI
- Smart Platform
- iqvia.ai
- IQVIA Connected Intelligence
- Healthcare-grade AI
- IQVIA Medical Reasoning LLM
- Carelon
- CarelonRx
- Carelon Behavioral Health
- Oracle Health EHR
- Fusion ERP
- OCI
- Tempus Platform
- xT liquid biopsy
- xR liquid biopsy
- xF liquid biopsy
- MRD testing
- Paige Predict
- AD-Detect
- Haystack MRD
- MyQuest app
- Labcorp OnDemand
- MyLabcorp
- Integrated Genetics
- Integrated Oncology
- Certara biosimulation
- Definitive Healthcare analytics
- Health Catalyst analytics
Search Keywords Policy Regulatory
- PAMA data reporting
- RESULTS Act
- ADLT designation
- MolDx reimbursement
- Medicare Advantage coverage
- American Cancer Society guidelines
- FDA approval diagnostics
- ONC-certified health IT
Search Keywords Event Phrases
- Guardant360 Liquid CDx FDA approval
- Shield UnitedHealth coverage
- Oracle AI infrastructure contracts
- Tempus Merck collaboration
- Tempus Gilead partnership
- Cerner acquisition
Google Trend Product Category Intent
• liquid biopsy cancer test
• multi-cancer early detection
• precision oncology
• AI drug discovery
• EHR software
• clinical trial data
• real-world evidence
• genetic testing for cancer
• minimal residual disease test
• Alzheimer's blood test
Google Trend Consumer Intent
• health data privacy
• personalized medicine
• genetic health insights
• how to get a liquid biopsy
• early cancer screening
• telehealth data
• chronic disease management apps
Google Trend Macro Policy Terms
• healthcare data interoperability
• Medicare reimbursement changes
• FDA diagnostic approvals
• AI in healthcare regulation
Top datasets to track
1. CMS Medicare Part B Claims Data Type: Government/Claims Data · Provider: Centers for Medicare & Medicaid Services (CMS) Cadence: Annual/Quarterly Why it matters: Directly impacts reimbursement rates for diagnostic tests (PAMA) and provides insights into utilization trends for Medicare Advantage plans, affecting companies like DGX, LH, HUM, ELV. Suggested query: CMS Medicare Part B claims data PAMA impact Confidence: High
2. FDA Device Approvals Database Type: Regulatory Data · Provider: U.S. Food and Drug Administration (FDA) Cadence: Continuous/Daily Why it matters: Tracks approvals for new diagnostic tests (e.g., liquid biopsies, CDx), which are critical catalysts for companies like GH, TEM, ABT, NTRA. Suggested query: FDA liquid biopsy approvals Confidence: High
3. Emerging Biopharma (EBP) Funding & Clinical Trial Starts Type: Industry/Financial Data · Provider: IQVIA Institute for Human Data Science, PitchBook, EvaluatePharma Cadence: Quarterly/Annual Why it matters: Leading indicator for demand in CRO services and data licensing for drug development, impacting IQV, CERT, LH, TEM. Suggested query: Emerging biopharma funding clinical trial starts Confidence: High
4. Healthcare AI Patent Filings & Research Publications Type: Innovation/Research Data · Provider: USPTO, WIPO, PubMed, arXiv Cadence: Continuous Why it matters: Signals innovation and competitive landscape in AI-driven healthcare solutions, relevant for IQV, TEM, ELV, ORCL. Suggested query: AI in healthcare patent trends Confidence: Medium
5. National Health Expenditure Accounts (NHEA) Data Type: Economic Data · Provider: Centers for Medicare & Medicaid Services (CMS) Cadence: Annual Why it matters: Provides macro-level spending trends across healthcare sectors, influencing overall demand for data, claims processing, and clinical services. Suggested query: US healthcare spending trends Confidence: High
Upcoming Catalysts
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| ABT_ba778762 | could happen in the fall | 2026-09-01 | 2026-11-30 | Medicare reimbursement expansion for continuous glucose monitoring (CGM) for Type 2 non-insulin users in the US. | This represents a multibillion-dollar opportunity, unlocking coverage for approximately 10 million Medicare beneficiaries and accelerating commercial insurance adoption, which is expected to significantly boost CGM sales. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| ABT_6009f906 | in the fall | 2026-09-01 | 2026-11-30 | International rollout of Libre Duo, the world's first dual glucose ketone monitoring sensor. | The introduction of this innovative new technology internationally is expected to contribute to the growth and leadership of Abbott's diabetes care business. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| ABT_e32745b9 | in the third quarter | 2026-07-01 | 2026-09-30 | Transition from limited market release to full market release of the Bolt 2.0 PFA catheter in the US. | This full market release is expected to accelerate Abbott's growth trajectory and help the company outperform the market and recapture share in the electrophysiology segment. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| DGX_97da38db | late September, early August | 2026-08-01 | 2026-09-30 | CMS is expected to report on the PAMA data collection process, including an assessment of data quality and the number of labs that submitted data. | The outcome of this report could influence future Medicare reimbursement rates for laboratory testing, potentially impacting Quest Diagnostics' profitability and the broader industry. | Theme | 2026-07-23 | earnings_transcript | DGX (ticker) |
| GH_551c816d | in 2026 | 2026-01-01 | 2026-12-31 | Launch of Guardant Reveal Ultra, the tumor-informed MRD/therapy monitoring test, expected to ship this year. | Could drive higher oncology volumes and strengthen Guardant360/Reveal synergy, improving growth prospects and competitive moat. | Ticker | 2026-02-19 | earnings_transcript | GH (ticker) |
| LH_538b9123 | September 10 | 2026-09-10 | 2026-09-10 | Labcorp Investor Day in New York City. | Management will share more details about their strategy, which could provide insights into future growth drivers, capital allocation, and operational improvements, potentially impacting investor sentiment and stock valuation. | Ticker | 2026-04-30 | earnings_transcript | LH (ticker) |
| LH_e2f765c4 | in the very near future | 2026-07-24 | 2026-10-24 | Completion of the acquisition of select outreach laboratory services across Indiana and Northwest Ohio from Parkview Health. | This acquisition will expand Labcorp's patient and provider networks, increase access to its broad test portfolio, and drive volume growth for the Diagnostics business, positively impacting revenue and competitive position. | Ticker | 2026-04-30 | earnings_transcript | LH (ticker) |
| TEM_0bbe29e3 | at some point, we'll have a really nice assay market | 2026-07-01 | 2027-12-31 | Launch of Tempus's second-generation tumor-naive MRD assay. | This new assay aims to offer improved performance and compete more effectively in subtypes where tissue is sparse, potentially expanding market reach and driving volume. Bullish if launched with strong performance, bearish if further delays or poor performance. | Ticker | 2026-02-24 | earnings_transcript | TEM (ticker) |
| ABT_30e24e43 | potential to be able to get this approved by year end | 2026-10-01 | 2026-12-31 | FDA approval for the new Amulet 360 left atrial appendage device. | This approval enables a significant relaunch of a superior product in the $2 billion LAA closure market, positioning Abbott for substantial market share capture in the electrophysiology business. | Ticker | 2026-07-16 | earnings_transcript | ABT (ticker) |
| GH_707b8be0 | later this year | 2026-10-01 | 2026-12-31 | Guardant Health plans to launch Reveal Ultra, which is anticipated to be the most sensitive tumor-informed MRD test. | This new product launch is expected to redefine sensitivity in the tumor-informed MRD space, enhancing Guardant Health's competitive position and driving further volume growth in the MRD market. | Ticker | 2026-07-30 | earnings_transcript | GH (ticker) |
| NTRA_be394610 | later this year | 2026-10-01 | 2026-12-31 | Commercial launch of Signatera for colorectal cancer in Japan. | This launch is expected to drive market adoption and revenue in Japan, supported by existing society guidelines. | Ticker | 2026-08-06 | earnings_transcript | NTRA (ticker) |
| TEM_b3d020d3 | as we get into '27, we'll start to contribute | 2026-10-01 | 2027-03-31 | CMS granting of Advanced Diagnostic Laboratory Test (ADLT) status for Tempus's xF liquid biopsy assay. | ADLT status is crucial for securing favorable and consistent reimbursement, leading to a significant ASP lift and closing the reimbursement gap with competitors. Bullish if granted, bearish if delayed or denied. | Ticker | 2026-02-24 | earnings_transcript | TEM (ticker) |
| UNH_2039ecb0 | on track to exceed 90% by year-end | 2026-10-01 | 2026-12-31 | Optum Health is on track to expand AI-based ambient listening capabilities to over 90% of its employed providers. | This deployment is expected to improve clinical workflow, reduce clinician burnout, enhance operational performance, and support better patient care, contributing to Optum Health's margin improvement and leveraging AI. | Ticker | 2026-07-16 | earnings_transcript | UNH (ticker) |
| ORCL_6daefdbb | October 28 in Las Vegas | 2026-10-28 | 2026-10-28 | Oracle's Investor Day event scheduled for October 28, 2026, where the company is expected to provide updates on its strategy, financial outlook, and progress in its AI and cloud businesses. | This event offers a critical platform for Oracle to articulate its long-term vision and provide new insights that could significantly influence investor sentiment, valuation, and understanding of its strategic direction. | Ticker | 2026-06-10 | earnings_transcript | ORCL (ticker) |
| ORCL_1633ca57 | accelerate in the second half of the year as we bring further megawatts online at our data centers | 2026-12-01 | 2027-05-31 | Oracle's anticipated acceleration in total revenues and non-GAAP EPS during the second half of fiscal year 2027, driven by bringing more data center capacity online to meet customer demand. | Achieving this acceleration is crucial for Oracle to demonstrate effective conversion of its substantial Remaining Performance Obligations (RPO) into recognized revenue and earnings, validating its AI infrastructure investments and boosting investor confidence. | Ticker | 2026-06-10 | earnings_transcript | ORCL (ticker) |
| IQV_2593c7c7 | December 1-2, 2026 | 2026-12-01 | 2026-12-02 | COG: CRO Summit in North Carolina, focusing on AI integration and clinical trial innovation. | This summit will highlight cutting-edge topics such as AI integration and clinical trial innovation. Key announcements or presentations could reveal new opportunities and competitive advantages for CROs like IQVIA, leveraging advanced technologies and operational efficiencies. | Theme | 2026-05-05 | earnings_transcript | IQV (ticker) |
| IQV_8ae5960d | December 2, 2026 | 2026-12-02 | 2026-12-02 | IQVIA Investor Day. | This event is expected to provide updated strategic insights, long-term financial targets, and new product/technology roadmaps, which can significantly impact investor sentiment and valuation. | Ticker | 2026-07-28 | earnings_transcript | IQV (ticker) |
| DGX_ae4871f6 | early next year | 2027-01-01 | 2027-03-31 | Launch of a state-of-the-art lab in Southeast Michigan as part of the joint venture with Corewell Health. | This joint venture is a significant growth driver for Quest's hospital channel, contributing to volume growth and expanding collaborative lab solutions. | Ticker | 2026-04-21 | earnings_transcript | DGX (ticker) |
| DGX_c0c7190c | early next year | 2027-01-01 | 2027-03-31 | Quest Diagnostics anticipates scaling up its Corewell Health Co-Lab relationship to a joint venture and launching a new lab in Michigan. | This represents a significant expansion of a strategic partnership, expected to contribute positively to revenues and strengthen Quest's presence in the hospital channel. | Ticker | 2026-07-23 | earnings_transcript | DGX (ticker) |
| GH_8850e4c8 | following ADLT designation | 2027-01-01 | 2027-06-30 | Guardant Health plans to offer widespread availability of Guardant360 Liquid CDx to U.S. customers. | This commercial rollout, following ADLT designation, will drive greater adoption of the test, simplify the therapy selection portfolio, and contribute to oncology volume growth. | Ticker | 2026-07-30 | earnings_transcript | GH (ticker) |
| GH_4fe268e1 | first half of 2027 | 2027-01-01 | 2027-06-30 | Guardant Health remains on track to obtain ADLT designation for Guardant360 Liquid CDx. | This designation is expected to lead to an immediate increase in the average selling price (ASP) for Guardant360, improving gross margins and potentially accelerating the company's timeline to cash flow breakeven. | Ticker | 2026-07-30 | earnings_transcript | GH (ticker) |
| ELV_db604a61 | on January 1, 2027 | 2027-01-01 | 2027-01-01 | Colorado's AI Act takes effect. | This regulatory trend impacts data owners operating across multiple US states, necessitating increased investment in legal and technical compliance, but also creating defensible moats for compliant companies like Elevance Health. | Theme | 2026-07-15 | earnings_transcript | ELV (ticker) |
Constituents
- — Oracle Corporation
- ABTT2— Abbott Laboratories
- DGXT2— Quest Diagnostics Incorporated
- GHT2— Guardant Health, Inc.
- LHT2— Labcorp Holdings Inc.
- NTRAT2— Natera, Inc.
- TEMT2— Tempus AI, Inc.
- ELVT3— Elevance Health Inc.
- IQVT3— IQVIA Holdings Inc.
- UNHT3— UnitedHealth Group Incorporated
- CERTT3· no notes yet
- CIT3· no notes yet
- CNCT3· no notes yet
- CVST3· no notes yet
- DHT3· no notes yet
- DOCST3· no notes yet
- HCATT3· no notes yet
- HUMT3· no notes yet
- TDOCT3· no notes yet
- VEEVT3· no notes yet